0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Atea Pharmaceuticals Inc

Healthcare US AVIR

3.69USD
-0.01(0.27%)

Last update at 2024-04-25T20:00:00Z

Day Range

3.673.75
LowHigh

52 Week Range

2.775.19
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -119.49900M 138.59M -10.94700M -14.03400M -9.06400M
Minority interest - - - - -
Net income -115.90900M 121.19M -10.86400M -13.46000M -9.06400M
Selling general administrative 48.71M 45.78M 21.64M 4.44M 2.80M
Selling and marketing expenses - - - - -
Gross profit - 351.37M 48.63M - -
Reconciled depreciation 0.26M 0.03M 0.02M 0.02M 0.02M
Ebit -130.91000M 138.35M -11.03000M -14.60800M -9.47700M
Ebitda -130.65000M 138.38M -11.01100M -14.59100M -9.46000M
Depreciation and amortization 0.26M 0.03M 0.02M 0.02M 0.02M
Non operating income net other - 0.21M 0.08M - -
Operating income -130.65000M 138.38M -11.03000M -14.60800M -9.47700M
Other operating expenses 130.65M 212.99M 59.66M 14.61M 9.48M
Interest expense 11.15M 0.24M 0.08M 0.00000M 0.00000M
Tax provision -3.59000M 17.40M - - -
Interest income 11.15M 0.21M 0.08M 0.57M 0.41M
Net interest income 11.15M 0.21M 0.08M 0.57M 0.41M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.59000M 17.40M -0.08300M -0.57400M 0.41M
Total revenue 0.00000M 351.37M 48.63M 0.00000M 0.00000M
Total operating expenses 130.65M 212.99M 59.66M 14.61M 9.48M
Cost of revenue - - - - -
Total other income expense net 11.15M 0.21M 0.08M 0.57M 0.41M
Discontinued operations - - - - -
Net income from continuing ops -115.90900M 121.19M -10.94700M -14.03400M -9.06400M
Net income applicable to common shares -115.90900M 121.19M -10.94700M -14.03400M -9.06400M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 666.71M 772.89M 863.63M 22.07M 34.86M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 14.21M 8.03M 7.54M 0.25M 0.21M
Total liab 26.14M 62.81M 315.83M 71.64M 71.02M
Total stockholder equity 640.57M 710.08M 547.80M -49.57100M -36.16100M
Deferred long term liab - - - - -
Other current liab 15.21M 52.35M 14.37M 1.89M 1.37M
Common stock 0.08M 0.08M 0.08M 0.01000M 0.01000M
Capital stock 0.08M 0.08M 0.08M 0.01000M 0.01000M
Retained earnings -59.87900M 56.03M -65.16000M -54.21300M -40.17900M
Other liab 5.25M 5.93M 0.04M 0.10M 0.15M
Good will - - - - -
Other assets 1.69M 0.47M 0.11M 0.12M 0.11M
Cash 646.71M 764.38M 850.12M 21.66M 34.49M
Cash and equivalents - - - - -
Total current liabilities 18.48M 56.88M 315.80M 2.44M 1.76M
Current deferred revenue - - 301.37M - -
Net debt -643.58500M -764.37500M -850.11700M -21.66100M -34.49200M
Short term debt 0.72M - - - -
Short long term debt - - - - -
Short long term debt total 3.12M - - - -
Other stockholder equity 701.05M 653.96M 612.88M 4.63M 4.01M
Property plant equipment 4.09M 0.02M 0.05M 0.04M 0.06M
Total current assets 660.92M 772.40M 863.48M 21.91M 34.70M
Long term investments - - - - -
Net tangible assets 640.57M 710.08M 547.80M -49.57100M -36.16100M
Short term investments 458.25M - - - -
Net receivables - - 5.82M - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.55M 4.53M 0.06M 0.55M 0.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.68400M - -863.63200M -0.11300M -0.09600M
Additional paid in capital - - - - -
Common stock total equity - 0.08M 0.08M 0.01000M 0.01000M
Preferred stock total equity - - - - -
Retained earnings total equity - 56.03M -65.16000M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.69M 0.47M 0.11M 0.12M 0.11M
Deferred long term asset charges - - - - -
Non current assets total 5.79M 0.49M 0.15M 0.16M 0.16M
Capital lease obligations 3.12M - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -455.41000M -0.00400M -0.02600M -0.00200M -0.01200M
Change to liabilities -1.98300M -291.07800M 300.88M 0.16M -0.09000M
Total cashflows from investing activities -455.41000M -0.00400M -0.02600M -0.00200M -0.01200M
Net borrowings - - - - -
Total cash from financing activities 0.37M 1.47M 531.75M -0.01500M 27.48M
Change to operating activities -44.60300M 43.23M 5.14M 0.41M 0.81M
Net income -115.90900M 121.19M -10.94700M -14.03400M -9.06400M
Change in cash -576.02200M -85.54400M 828.46M -12.83100M 19.56M
Begin period cash flow 764.68M 850.22M 21.77M 34.60M 15.04M
End period cash flow 188.66M 764.68M 850.22M 21.77M 34.60M
Total cash from operating activities -120.98200M -87.00500M 296.73M -12.81400M -7.90800M
Issuance of capital stock 0.23M 1.47M 531.75M 0.00000M 27.48M
Depreciation 0.26M 0.03M 0.02M 0.02M 0.02M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - 5.14M - -
Change to account receivables - - -5.81500M -5.81500M -5.81500M
Sale purchase of stock - 1.47M 531.75M - -
Other cashflows from financing activities 0.14M -0.00400M 214.12M -0.01500M 27.36M
Change to netincome 41.25M 39.62M 7.46M 0.62M 0.41M
Capital expenditures 1.94M 0.00400M 0.03M 0.00200M 0.01M
Change receivables - - -5.81500M - -
Cash flows other operating - -302.01100M 294.07M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -85.54400M 828.46M - -
Change in working capital -46.58600M -247.84500M 300.20M 0.58M 0.72M
Stock based compensation 46.72M 39.62M 7.46M 0.62M 0.41M
Other non cash items -5.46500M -415.68300M -228.00200M 14.04M -
Free cash flow -122.92500M -87.00900M 296.71M -12.81600M -7.92000M

Fundamentals

  • Previous Close 3.70
  • Market Cap262.82M
  • Volume171306
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-137.86600M
  • Revenue TTM192.18M
  • Revenue Per Share TTM2.31
  • Gross Profit TTM -81.93600M
  • Diluted EPS TTM-1.57

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVIR
Atea Pharmaceuticals Inc		 -0.01 0.27% 3.69 - - 1.90 0.43 58.97 2.17
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc

125 Summer Street, Boston, MA, United States, 02110

Key Executives

Name Title Year Born
Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, CEO & Pres 1956
Ms. Andrea J. Corcoran J.D. CFO, Exec. VP of Legal & Sec. 1962
Mr. John F. Vavricka Chief Commercial Officer 1964
Dr. Janet M. J. Hammond M.D., Ph.D. Chief Devel. Officer 1960
Dr. Maria Arantxa Horga M.D. Chief Medical Officer 1968
Mr. Wayne Foster CPA, CPA Exec. VP of Fin. & Chief Accounting Officer 1969
Ms. Jonae R. Barnes Sr. VP of Investor Relations & Corp. Communications NA
Mr. Ariyapadi N. Krishnaraj VP of Marketing NA
Mr. Adel Moussa Ph.D. Exec. VP of Chemistry NA
Mr. Xiao-Jian Zhou Ph.D. Exec. VP of Early Stage Devel. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).